Analysts remain positive on Sun Pharma despite slower US and speciality growth in Q2FY27, supported by strong domestic sales, though near-term earnings estimates have been cut.
Street stays bullish on Sun Pharma despite mixed Q2, earnings downgrades
BU
Business Standard - LatestBy Devangshu Datta
EXECUTIVE SUMMARY
Analysts remain positive on Sun Pharma despite slower US and speciality growth in Q2FY27, supported by strong domestic sales, though near-term earnings estimates have been cut.
Key Takeaways
- Street stays bullish on Sun Pharma despite mixed Q2, earnings downgrades.
- Analysts remain positive on Sun Pharma despite slower US and speciality growth in Q2FY27, supported by strong domestic sales, though near-term earnings estimates have been cut.
- Analysts remain positive on Sun Pharma despite slower US and speciality growth in Q2FY27, supported by strong domestic sales, though near-term earnings estimates have been cut.
Read Complete Original Article
Published originally on Business Standard - Latest
